title: Relative erythrocytosis of patients with end stage renal failure undergoing CAPD.
abstract: OBJECTIVE
  Although the majority of patients with end stage renal failure have anemia, some have relative erythrocytosis. Patients treated with continuous ambulatory peritoneal dialysis (CAPD) having relative erythrocytosis were studied in order to determine the factors that would be responsible.
  
  
  METHODS
  Nine out of 89 CAPD patients (10%) were identified as having relative erythrocytosis. Age-, sex- and duration of disease-matched eight patients undergoing CAPD were taken as control. Beside factors of etiologies of renal failure, smoking, renal cysts, viral hepatitides, residual renal function, the adequacy of CAPD, nutritional status, hypertension, serum levels of erythropoietin, IL-1, IL-6, TNF-, and IGF-1 levels were also investigated.
  
  
  RESULTS
  Relative erythrocytosis occurred most often in diabetic and amyloidosis patients. None of the parameters studied were found to be significantly different between groups. During 2-year follow-up, although statistically non-significant, patients having relative erythrocytosis seemed to have higher mortality rate due to vascular complications.
  
  
  CONCLUSIONS
  No single factor seemed to explain erythrocytosis in patients undergoing CAPD. Being diabetic or with amyloidosis may increase the risk.
authors.affiliation: Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey.
authors.forename: Mehmet Riza
authors.initials: MR
authors.lastname: Altiparmak
authors.forename: Rezzan
authors.initials: R
authors.lastname: Ataman
authors.forename: Resat
authors.initials: R
authors.lastname: Ozaras
authors.forename: Veysel
authors.initials: V
authors.lastname: Tahan
authors.forename: Seval
authors.initials: S
authors.lastname: Aydin
authors.forename: Hafize
authors.initials: H
authors.lastname: Uzun
authors.forename: Kamil
authors.initials: K
authors.lastname: Serdengecti
authors.forename: Teoman
authors.initials: T
authors.lastname: Soysal
mesh_terms: D000328:Adult; D000686:Amyloidosis / Q000150:complications; D015703:Antigens, CD; D048909:Diabetes Complications; D004921:Erythropoietin / Q000032:analysis; D005260:Female; D006525:Hepatitis, Viral, Human / Q000150:complications; D006801:Humans; D006973:Hypertension / Q000150:complications; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D007375:Interleukin-1 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D007668:Kidney / Q000503:physiopathology; D052177:Kidney Diseases, Cystic / Q000150:complications; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy*; D008297:Male; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011086:Polycythemia / Q000209:etiology*; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D012307:Risk Factors; D012907:Smoking
chemical_list: D015703:Antigens, CD; D007375:Interleukin-1; D015850:Interleukin-6; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D004921:Erythropoietin; D007334:Insulin-Like Growth Factor I